跳至主要内容
临床试验/IRCT20231003059605N1
IRCT20231003059605N1已完成1 期

COMPARISON OF ORAL VERSUS INTRAVENOUS IRON THERAPY IN IMPROVING HEMOGLOBIN STATUS IN PATIENTS OF CHRONIC KIDNEY DISEASE

Pak Emirates Military Hospital Rawalpindi0 个研究点目标入组 210 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Inclusion criteria included all male and female patients over the age of 18 years
  • Not on hemodialysis or erythropoietin diagnosed as anemia with a baseline Hb of less than 13 g/dl in males and less than 12 g/dl in females
  • With established chronic kidney disease with a GFR (glomerular filtration rate) of less than 60ml/min for more than 90 days assessed using the CKD-EPI equation and/or hyper albuminuria with urine albumin ? 30 mg in 24 hours or urine albumin to creatinine ratio (ACR) ? 30 mg/g.

排除标准

  • Exclusion criteria included patients on dialysis, erythropoietin or use of erythropoietin stimulating agents (ESAs) in the last 3 months
  • Patients with advanced liver, cardiac or ESKD (end-stage kidney disease)
  • Drug allergies to iron and its supplemental form during therapy or previous known history
  • Unwilling to be included in the study.

研究者

发起方
Pak Emirates Military Hospital Rawalpindi

相似试验